Graft-Versus-Host Disease | Medulloblastoma | Cervical Cancer Screening, 03/02/2022

National Cancer Institute sent this bulletin at 03/02/2022 10:30 AM EST
National Cancer Institute

Having trouble viewing this email? View it as a Web page.

Bookmark and Share
Cancer Information Highlights
From the National Cancer Institute
Updating you about cancer causes, prevention, screening, treatment, coping, and more
 
New from NCI
Can Chronic Graft-Versus-Host Disease Be Prevented?
A T cell attacking an infected cell, including naive T cells which have never enountered an antigen.   Removing certain T cells from donated stem cells before they are transplanted may prevent chronic graft-versus-host disease in people with leukemia. Learn about stem cell transplants and the research behind this treatment approach.
Experimental Medulloblastoma Treatment Gets a Boost with Nanoparticles
The nanoparticle is made of a flexible polymer that assembles into tiny soap bubble-like shapes with the drug cradled in the center.   A nanoparticle coating may help cancer drugs reach medulloblastoma tumors in the brain and make the treatment less toxic. Mice treated with nanoparticles containing palbociclib (Ibrance) and sapanisertib lived much longer than those treated with either drug alone.
Why Are Many Women Overdue for Cervical Cancer Screening?

The number of women who were overdue for cervical cancer screening grew between 2005 and 2019. Learn about the groups of women who were more likely to be overdue and what the most common reasons were for not receiving screening on time.
PDQ Updates
Gestational Trophoblastic Disease Treatment

We’ve updated our page on gestational trophoblastic disease with revisions to the section that describes the stages of this disease.
FDA Approvals
Sirolimus Protein-Bound Particles

We added a new drug summary for sirolimus protein-bound particles (Fyarro). The Food and Drug Administration recently approved this drug to treat adults with perivascular epithelioid cell tumors that have spread to other parts of the body or cannot be removed by surgery.
 
Also of Interest
Rare Tumors

As a group, rare tumors make up over 25% of all cancers. Learn about types of rare tumors, where they occur in the body, how they form, and how they are treated.
COVID-19: What People with Cancer Should Know

The COVID-19 situation in the United States continues to change, and so does guidance from experts as they learn more. Learn the latest on how to protect yourself from COVID-19 and find advice on vaccine booster shots.
Contact Us for Help

Information specialists at NCI’s Cancer Information Service (CIS), NCI's contact center, are available to help answer your cancer-related questions in English and Spanish. Reach us by phone, chat, or email.